News

Pfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.

Shares of Pfizer have been

When it comes to dividend investing, some investors like to invest for income, and if you are searching for income, this is the video for you. Today, we will be looking at three dividend stocks that

The pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (NYSE: PFE) benefitted a few years ago has trickled down to a small stream. As a result, share prices have fallen and

Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors.

*Stock prices used were the afternoon prices of May 28, 2024. The video was published on May

As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with

Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before

A vaccine and an antiviral treatment for COVID-19 made Pfizer (NYSE: PFE) a household name in recent years, but this isn't all the company sells. There are dozens of innovative medicines in its

When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We

The past couple of years haven't been easy ones to be a Pfizer (NYSE: PFE) shareholder. The windfall profits its COVID-19 products produced in the early days of the pandemic evaporated much faster

Investors looking to pad their passive income streams with high-yield dividend stocks have three excellent choices. If you have an extra $100 to invest, you could set yourself up with dividends from

The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You

Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon

Pfizer (NYSE: PFE) stock has struggled over the past year, losing around 28% of its value. Its dividend payout, meanwhile, has continued to rise again and again. This combination has pushed the

It's easy to find stocks that are lagging broader equities, even in a bull market like the one we're currently in. It's harder to find beaten-down stocks that still look worth buying and holding

Dividends may be boring but are essential to building a well-balanced portfolio. After all, dividend payments have accounted for approximately 85% of the S&P 500's total returns since 1960, per a

After steadily raising its payout by 163% over the past 15 years, Pfizer (NYSE: PFE) continues to be one of the most reliable pharma stocks an income-seeking investor can reach for these days. The

Healthcare doesn't get the hype that other industries -- say, technology -- get. However, there arguably isn't an industry more important to humankind's well-being. That's especially true in the

Don't believe the adage to "sell in May and go away." Buying stocks can still be a smart move, especially if you're a long-term investor.

Three Motley Fool contributors have identified stocks they

Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly's share price more than

Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its stock in serious bargain territory. Speaking

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q1 2024 Earnings CallMay 01, 2024, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

Pfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on

Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names.

However, long-term investors know that the best way to view a quarterly

I owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar over 60% in roughly two years was fun. Seeing Pfizer's share price fall nearly 60% from its peak

Income investors can be growth investors, too. Granted, it's not always easy to find stocks that pay generous dividends and offer solid prospects of share price appreciation. However, such stocks